Skip to main content

Remote Job Finders (RJF)

Biopharma professionals increasingly accept underemployment

The number of biotech and pharma professionals taking jobs they’re overqualified for is now over 50%, based on a BioSpace LinkedIn poll. A recruiting firm executive discusses the trend, the reasons behind it and why it doesn’t have to derail careers.

FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.

Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues

Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.

Biotech can’t continue to innovate under strain of Big Pharma market pressures

Biotech is increasingly financed, governed and regulated as though it were a mature pharmaceutical industry rather than a discovery system built around scientific uncertainty. Structural changes are needed to sustain the sector’s strategic innovation.
Scroll to top